Literature DB >> 30541570

Associating conditional cash transfer to universal access to treatment could be the solution to the HCV epidemic among drug users (DUs).

Philippe Chossegros1, Fiorant Di Nino2.   

Abstract

BACKGROUND: To understand the limits of HCV screening programs to reach all drug users (DUs).
METHOD: The association of the recruitment of a representative sample of a population of DUs in a specific area with the use of a questionnaire that included 250 items allowed the use of uni- and multifactorial analysis to explore the relationship between HCV screening and dimensions until now restricted to qualitative studies.
RESULTS: We recruited, in less than 2 months, 327 DUs representing about 6% of the total population of DUs. They belonged to a single community whose drug use was the only common characteristic. While almost all DUs (92.6%) who had access to care providers had been screened, this proportion was much lower in out-of-care settings (64%). HCV prevalence among those who had performed a test was low (22.8%). For DUs, the life experience of hepatitis C has not changed in the last 10 years. Screening, studied for the first time according to this life experience, was not influenced by a rational knowledge of the risk taken or the knowledge of treatment efficacy, showing a gap between DUs' representations and medical recommendations which explains the low level of active screening. Police crackdown on injections, disrupting the previous illusion of safe practices, was the only prior history leading to active screenings. Screenings were related to an access to care providers. GPs held a preponderant position as a source of information and care by being able to give appropriate answers regarding hepatitis C and prescribing opioid substitution treatments (OST). If 48 % of DUs screened positive for HCV had been treated, half of them had been prescribed before 2006.
CONCLUSION: While hepatitis has become a major issue for society and, consequently, for services for DUs (SDUs) and GPs, it is not the case for DUs. A widespread screening, even in a city where the offer of care is diversified and free, seems unlikely to reach a universal HCV screening over a short time. The model of respondent-driven sampling recruitment could be a new approach to conditional cash transfer, recruiting and treating DUs who remain outside the reach of care providers, a prerequisite for the universal access to HCV treatments to impact the HCV epidemic.

Entities:  

Keywords:  Drug use; Epidemic; HCV; Respondent-driven sampling; Social networks

Mesh:

Year:  2018        PMID: 30541570      PMCID: PMC6292040          DOI: 10.1186/s12954-018-0264-4

Source DB:  PubMed          Journal:  Harm Reduct J        ISSN: 1477-7517


  52 in total

Review 1.  Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment.

Authors:  Brennan M R Spiegel; Zobair M Younossi; Ron D Hays; Dennis Revicki; Sean Robbins; Fasiha Kanwal
Journal:  Hepatology       Date:  2005-04       Impact factor: 17.425

2.  A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.

Authors:  Donna M Evon; Kelly Simpson; Scott Kixmiller; Joseph Galanko; Karen Dougherty; Carol Golin; Michael W Fried
Journal:  Am J Gastroenterol       Date:  2011-07-19       Impact factor: 10.864

3.  Knowledge of and interest in hepatitis C treatment at a methadone clinic.

Authors:  Alexander Y Walley; Mary C White; Margot B Kushel; Yong S Song; Jacqueline P Tulsky
Journal:  J Subst Abuse Treat       Date:  2005-03

4.  Limited uptake of hepatitis C treatment among injection drug users.

Authors:  Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas
Journal:  J Community Health       Date:  2008-06

Review 5.  Survival rate of AIDS disease and mortality in HIV-infected patients: a meta-analysis.

Authors:  J Poorolajal; E Hooshmand; H Mahjub; N Esmailnasab; E Jenabi
Journal:  Public Health       Date:  2016-06-24       Impact factor: 2.427

6.  The collective dynamics of smoking in a large social network.

Authors:  Nicholas A Christakis; James H Fowler
Journal:  N Engl J Med       Date:  2008-05-22       Impact factor: 91.245

7.  Higher magnitude cash payments improve research follow-up rates without increasing drug use or perceived coercion.

Authors:  David S Festinger; Douglas B Marlowe; Karen L Dugosh; Jason R Croft; Patricia L Arabia
Journal:  Drug Alcohol Depend       Date:  2008-04-18       Impact factor: 4.492

Review 8.  Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations.

Authors:  Stephanie Coward; Laura Leggett; Gilaad G Kaplan; Fiona Clement
Journal:  BMJ Open       Date:  2016-09-06       Impact factor: 2.692

9.  Using peer advocates to improve access to services among hard-to-reach populations with hepatitis C: a qualitative study of client and provider relationships.

Authors:  Jennifer MacLellan; Julian Surey; Ibrahim Abubakar; Helen R Stagg; Jenevieve Mannell
Journal:  Harm Reduct J       Date:  2017-11-28

10.  Perceptions of drug users regarding hepatitis C screening and care: a qualitative study.

Authors:  Ashly E Jordan; Carmen L Masson; Pedro Mateu-Gelabert; Courtney McKnight; Nicole Pepper; Katie Bouche; Laura Guzman; Evan Kletter; Randy M Seewald; Don C Des-Jarlais; James L Sorensen; David C Perlman
Journal:  Harm Reduct J       Date:  2013-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.